1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nanatinostat (Nstat) and valganciclovir (VGCV) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV (+)) lymphomas: Final results from the phase 1b/2 VT3996-201 study
    Meeting Abstract

    Haverkos, B. M.; Alpdogan, O.; Baiocchi, R.; Brammer, J. E.; Feldman, T. A.; Capra, M.; Brem, E. A.; Nair, S. M.; Scheinberg, P.; Pereira, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • T-cell lymphomas: Online education significantly improves clinicians' knowledge of therapeutic advances
    Meeting Abstract

    Heller, E. J.; Williams, S. L.; Smith, K. P.; Horwitz, S. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A long-term follow-up of the randomized, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
    Meeting Abstract

    Hermine, O.; Jiang, L.; Walewski, J.; Bosly, A.; Szymczyk, M.; Thieblemont, C.; Pott, C.; Salles, G.; Feugier, P.; Hübel, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Risks for hospitalization and death among patients with blood disorders from the ASH RC COVID-19 Registry for Hematology
    Meeting Abstract

    Hicks, L. K.; Redd, R. A.; Anderson, K. C.; Desai, P.; Dolan, B.; Goldberg, A. D.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Sehn, L. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy or in combination with rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Hamlin, P. A.; Patel, M. R.; Stevens, D.; Hess, B. T.; Munoz, J.; Feldman, T. A.; Smith, S. M.; Coffey, G. P.; Osman, M.; Holland, J. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I and expansion study of eprenetapopt (APR-246) in combination with venetoclax (VEN) and azacitidine (AZA) in TP53-mutant acute myeloid leukemia (AML)
    Meeting Abstract

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the mutation agnostic FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Ohanian, M.; Koller, P.; Altman, J. K.; Cherry, M.; Tomlinson, B.; Chandhok, N.; Zhang, H.; Rastgoo, N.; Benbatoul, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia
    Meeting Abstract

    Grenet, J.; Jain, A. G.; Burkart, M.; Waksal, J.; Famulare, C.; Numan, Y.; Stahl, M.; Mckinnell, Z.; Ball, B.; Ma, X.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Patients with AML who achieve long term complete remission do not have a normal life expectancy when compared to the general population. Analysis of 3,012 patients enrolled on 9 consecutive ECOG-ACRIN trials
    Meeting Abstract

    Ganzel, C.; Roopcharan, K.; Sun, Z.; Rowe, J. M.; Fernandez, H. F.; Paietta, E. M.; Luger, S. M.; Lazarus, H. M.; Cripe, L. D.; Douer, D.; more...
    Blood (2021)

    Fulltext@MSK | Save